Zacks Research Issues Pessimistic Estimate for TMO Earnings

Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) - Stock analysts at Zacks Research cut their Q4 2025 earnings per share estimates for Thermo Fisher Scientific in a research report issued to clients and investors on Wednesday, May 14th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings per share of $6.42 for the quarter, down from their previous estimate of $6.68. The consensus estimate for Thermo Fisher Scientific's current full-year earnings is $23.28 per share. Zacks Research also issued estimates for Thermo Fisher Scientific's Q1 2026 earnings at $5.70 EPS, Q2 2026 earnings at $7.00 EPS, Q3 2026 earnings at $5.73 EPS, Q4 2026 earnings at $6.13 EPS, FY2026 earnings at $24.55 EPS and FY2027 earnings at $27.88 EPS.

A number of other equities research analysts have also issued reports on TMO. Barclays decreased their price target on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. Raymond James reaffirmed an "outperform" rating and set a $667.00 target price (up from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Royal Bank of Canada decreased their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Stifel Nicolaus decreased their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. Finally, Evercore ISI decreased their target price on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Five analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $607.43.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $412.15 on Monday. Thermo Fisher Scientific has a 52-week low of $390.50 and a 52-week high of $627.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The firm has a market capitalization of $155.58 billion, a P/E ratio of 24.93, a P/E/G ratio of 2.99 and a beta of 0.82. The stock has a 50 day moving average price of $453.88 and a 200 day moving average price of $509.89.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. The business had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The firm's revenue for the quarter was up .2% compared to the same quarter last year. During the same quarter last year, the business posted $5.11 EPS.

Hedge Funds Weigh In On Thermo Fisher Scientific

A number of large investors have recently bought and sold shares of TMO. Wedge Capital Management L L P NC raised its holdings in Thermo Fisher Scientific by 4.1% in the 4th quarter. Wedge Capital Management L L P NC now owns 706 shares of the medical research company's stock worth $367,000 after purchasing an additional 28 shares during the period. Merit Financial Group LLC increased its stake in Thermo Fisher Scientific by 54.4% during the 4th quarter. Merit Financial Group LLC now owns 9,851 shares of the medical research company's stock worth $5,125,000 after buying an additional 3,470 shares in the last quarter. Sanibel Captiva Trust Company Inc. increased its stake in Thermo Fisher Scientific by 5.4% during the 4th quarter. Sanibel Captiva Trust Company Inc. now owns 1,935 shares of the medical research company's stock worth $1,007,000 after buying an additional 99 shares in the last quarter. HB Wealth Management LLC increased its stake in Thermo Fisher Scientific by 2.0% during the 4th quarter. HB Wealth Management LLC now owns 13,027 shares of the medical research company's stock worth $6,777,000 after buying an additional 256 shares in the last quarter. Finally, Smith Salley Wealth Management increased its stake in Thermo Fisher Scientific by 13.9% during the 4th quarter. Smith Salley Wealth Management now owns 48,671 shares of the medical research company's stock worth $25,320,000 after buying an additional 5,954 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Insiders Place Their Bets

In other news, SVP Michael A. Boxer sold 3,775 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the transaction, the senior vice president now owns 10,816 shares of the company's stock, valued at $5,759,736.32. The trade was a 25.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president now directly owns 23,167 shares of the company's stock, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 14,075 shares of company stock valued at $7,305,942. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were given a dividend of $0.43 per share. The ex-dividend date was Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a yield of 0.42%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's payout ratio is currently 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.